Guided Therapeutics will take development of its esophageal cancer detection device in-house under the terms of new deal with Konica Minolta.
Guided Therapeutics (OTC:GTHP) and its largest customer, Konica Minolta (TYO:4902), agreed to alter a development deal for an esophageal cancer detection device.
Under the terms of the deal, Norcross, Ga.-based Guided Therapeutics will assume development responsibilities for an Esophageal Dysplasia Detection System from Konica Minolta and control the worldwide sales and marketing rights to the device. In addition, Guided Therapeutics will license the rights to certain intellectual property developed by Konica Minolta.
